ライフサイエンスコーパス: testosterone propionate

1 rat treated with N-methyl-N-nitrosourea and testosterone propionate.

2 adectomized rats that were supplemented with testosterone propionate.

3 changed after injection of 300 micrograms of testosterone propionate.

4 erone acetate (50 mg/kg/day for 21 days) and testosterone propionate (100 mg/kg/day for 3 days), grou

5 half examines the neuroprotective effects of testosterone propionate, 17-beta estradiol, and dihydrot

6 Treatment of GDNX rats with testosterone propionate (500 microg/d, s.c., 2 d) increa

7 Both estradiol benzoate (20 microg/kg) and testosterone propionate (500 microg/kg), but not dihydro

8 -1 + UGM tissue recombinants were exposed to testosterone propionate and 17-beta-estradiol (T + E2),

9 female pups were injected with 100 microg of testosterone propionate, and male and control female pup

10 The addition of testosterone propionate does not affect tumor incidence

11 equential regimen of cyproterone acetate and testosterone propionate, followed by a single i.v. injec

12 dly, prenatal or early postnatal exposure to testosterone propionate had no effect on adult females'

13 nd adult female rats neonatally treated with testosterone propionate on the first day after birth dis

14 A single injection of testosterone propionate or estradiol benzoate on the day

15 iron-deficient mice were treated weekly with testosterone propionate or vehicle for 3 weeks.

16 ale rat pups were treated with the androgen, testosterone propionate, or the oil vehicle alone.

17 s of a high, medium, or low dose of the AAS, testosterone propionate, or the oil vehicle.

18 ngly, neonatal gonadectomy, with and without testosterone propionate replacement, was followed by fin

19 100 mg Testosterone propionate (T) or vehicle (C) was administe

20 emale rats received sc injections of 1.25 mg testosterone propionate (Testos; n = 10), 0.5 mg estradi

21 yndrome (PCOS), (pregnant ewes injected with testosterone propionate (TP) (100 mg twice weekly) from

22 al males (P7-P14) received 200 micrograms of testosterone propionate (TP) 2 hours prior to death to e

23 Furthermore, it has been documented that testosterone propionate (TP) augments peripheral motoneu

24 intact breeding males by daily injections of testosterone propionate (TP) for 5 weeks.

25 hat treating neonatally castrated males with testosterone propionate (TP) in adulthood did not revers

26 ferrets (Mustela putorius furo) given either testosterone propionate (TP) or oil vehicle preferred to

27 e rats were exposed to a single injection of testosterone propionate (TP) or oil within 24 h of birth

28 The ability of postnatal testosterone propionate (TP) to masculinize both behavio

29 n with protracted (3-week) administration of testosterone propionate (TP) to socially isolated (SI) a

30 Testosterone propionate (TP) treatment prevented LNCaP 1

31 Testosterone propionate (TP) treatment resulted in numbe

32 In this study, the ability of testosterone propionate (TP), alone or in conjunction wi

33 Testosterone propionate (TP), augments facial nerve rege

34 sses of steroid agonists applied (androgen - Testosterone propionate (TP), estrogen - Diethystilbeste

35 ta-estradiol benzoate (EB), or 250 microg of testosterone propionate (TP), or both EB and TP, or sesa

36 cement therapy with estradiol benzoate (EB), testosterone propionate (TP), or sesame oil (SO) vehicle

37 studied: intact, castrated, or castrated and testosterone propionate (TP)-treated normal adult male m

38 Treatment of OVX rats with testosterone propionate (TP; 500 microg/d, s.c., 2 d) si

39 Treatment with testosterone-propionate (TP) reveals sex-specific gene e

40 Short-term (2 d) testosterone propionate treatment reversed the decline i

41 ied in gonadectomized rats supplemented with testosterone propionate, with 17-beta-estradiol, or with